Table 4 Comparison between the tocilizumab and infliximab/tocilizumab groups among patients with severe COVID-19 symptoms in monitoring parameters post-treatment (Subgroup analysis).
Variable as (mean ± SD) | Tocilizumab n = 29 | Tocilizumab/infliximab n = 34 | Significance P value |
|---|---|---|---|
Time to improvement | 7.35 ± 4.7 | 7.13 ± 4.1 | P = 0.147 |
Length of hospital stay | 8.61 | 6.85 | P = 0.04* |
PF | 210.8 ± 78.8 | 204 ± 97.2 | P = 0.381 |
C-reactive protein (CRP) | 47.8 ± 8.2 | 20.6 ± 6.2 | P = 0.004* |
Lactate dehydrogenase (LDH) | 457.1 ± 177.5 | 259.7 ± 105.2 | P = 0.0.005* |
D-dimmer | 1.67 ± 3.2 | 1.44 ± 4.6 | P = 0.306 |
Ferritin | 937.9 ± 46.8 | 790.4 ± 78.9 | P = 0.399 |
Total leucocytic count (TLC) | 11.2 ± 4.9 | 10.6 ± 5.3 | P = 0.07 |
Absolute lymphocytic count (ALC) | 12.2 ± 10.8 | 7.3 ± 12.7 | P = 0.004* |
Neutrophils lymphocytic ratio (NLR) | 14.5 ± 1.5 | 10.1 ± 1.7 | P = 0.01* |
Alanine transaminase (ALT) | 83.6 ± 9.9 | 140.7 ± 8.3 | P = 0.003* |
Aspartate transaminase (AST) | 57.4 ± 6.2 | 112.2 ± 6.8 | P = 0.0001* |
Troponin | 0.01 ± 0.01 | 0.07 ± 0.01 | P = 0.27 |
